Neurotech 2026–2030: BCI Opportunities & Exit Pathways

Brain–computer interfaces are about to separate the science projects from the companies that exit. In one live, interactive hour, a panel of well-known investors and leading neurotech KOLs maps where neurotech actually creates value between 2026 and 2030 — the categories investors are quietly building positions in, the clinical and regulatory milestones that de-risk a deal, and the acquirers most likely to write the checks. Come with questions; leave with a thesis.